J. Linden
Research Subjects
J. Linden has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anne Schuind
GSK, Rockville, MD, USA
1 shared publication - Anuradha Madan
GSK, 1250 South Collegeville Road, Collegeville, PA 19426, USA
1 shared publication - Baudouin Standaert
Department of Care & Ethics, Faculty of Medicine & Life Sciences, University of Hasselt, 3590 Diepenbeek, Belgium
1 shared publication - Genevieve Meier
Formerly at Global Value and Access, Eisai, New York, USA
1 shared publication - J. Malak
University of Wisconsin-Madison, Madison, WI, USA
1 shared publication - Laurence Chu
Benchmark Research, Austin, TX, USA
1 shared publication
Latest Publications
- Open Access
- 6 May 2019
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 17 (1) , 80
Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study
This study aims to describe the short-term reactogenicity of the AS03-adjuvanted H5N1 vaccine expressed through adverse events (AEs) and quality-adjusted life-day (QALD) scores. The AEs are likely to be short-term and therefore the quality of life (QoL) questionnaire, SF-36v2, was administered daily to record changes over seven days. A more sensitive application of this instrument should allow for a better understanding of short-term tolerability of adjuvanted vaccines. Participants (N = 50) received a 2-dose vaccination schedule. Solicited (collected daily: days 0 to 7 [post dose 1] and 21 to 28 [post dose 2]) and unsolicited (collected weekly until day 21) AEs were collected via diary cards. The QoL questionnaires were completed daily (days 0–6) and weekly (days 0, 6, 21, 27) after dose one. Questionnaire data were transformed into SF-6D scores to report QALDs. It was hypothesized post-hoc that the QALD and daily AEs scores should correlate if discrete QoL-changes were captured. Pain (92%) and muscle ache (66%) were the most commonly reported solicited local and general AEs respectively, neither increased in intensity nor in frequency after dose 2. No safety concerns were identified during the study. A correlation between the daily AEs and QALD scores existed (correlation coefficient, − 0.97 (p < 0.001)). The impact of the AEs scores on the QALD was marginal (− 0.02 max for one day). Similarly with other H5N1 studies, no safety concern was identified throughout the study. Some time-limited variations in QALD-scores were reported. Our results imply that daily administration of the SF-36v2 captures changes in QALD-scores. ClinicalTrials.gov . NCT01788228. Registered 11 February 2013.
- 6 May 2019
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 17 (1) , 80
Open AccessUsability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study
This study aims to describe the short-term reactogenicity of the AS03-adjuvanted H5N1 vaccine expressed through adverse events (AEs) and quality-adjusted life-day (QALD) scores. The AEs are likely to be short-term and therefore the quality of life (QoL) questionnaire, SF-36v2, was administered daily to record changes over seven days. A more sensitive application of this instrument should allow for a better understanding of short-term tolerability of adjuvanted vaccines. Participants (N = 50) received a 2-dose vaccination schedule. Solicited (collected daily: days 0 to 7 [post dose 1] and 21 to 28 [post dose 2]) and unsolicited (collected weekly until day 21) AEs were collected via diary cards. The QoL questionnaires were completed daily (days 0–6) and weekly (days 0, 6, 21, 27) after dose one. Questionnaire data were transformed into SF-6D scores to report QALDs. It was hypothesized post-hoc that the QALD and daily AEs scores should correlate if discrete QoL-changes were captured. Pain (92%) and muscle ache (66%) were the most commonly reported solicited local and general AEs respectively, neither increased in intensity nor in frequency after dose 2. No safety concerns were identified during the study. A correlation between the daily AEs and QALD scores existed (correlation coefficient, − 0.97 (p < 0.001)). The impact of the AEs scores on the QALD was marginal (− 0.02 max for one day). Similarly with other H5N1 studies, no safety concern was identified throughout the study. Some time-limited variations in QALD-scores were reported. Our results imply that daily administration of the SF-36v2 captures changes in QALD-scores. ClinicalTrials.gov . NCT01788228. Registered 11 February 2013.